Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine pilot study for methamphetamine use disorder
ACTRN12621000528853Phase 2Completed
- Sponsor
- Orygen
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in stimulant use disorder (SUD) and methamphetamine use disorder (MUD), sponsored by Orygen. Started Mar 2022; status: completed.
02
Drugs
ketamine
03
Conditions
stimulant use disorder (SUD)methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on ACTRN12621000528853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000528853.